SGLT2 INHIBITORS PRODUCE CARDIORENAL BENEFITS BY PROMOTING ADAPTIVE CELLULAR REPROGRAMMING TO INDUCE A STATE OF FASTING MIMICRY: A PARADIGM SHIFT IN UNDERSTANDING THEIR MECHANISM OF ACTION